Allovir Inc (ALVR) Stock Price, Quote & News

11thestate Jun. 12 at 10:36 PM

Don’t forget that if you held $ALVR, there’s a significant settlement you can also claim. Consider it the dividend #AlloVir never paid. https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate Jun. 4 at 12:04 PM

Don’t forget that if you held $ALVR, there’s a significant settlement you can also claim. Consider it the dividend #AlloVir never paid. https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate May. 27 at 10:35 AM

$ALVR investors, if you follow us, you already knew about it. This is the good news you needed about $ALVR today. Go check it out. #AlloVir #ALVR https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate May. 20 at 4:29 PM

$ALVR agreed to a $1M settlement with investors over claims it made false or misleading statements about its business. Who’s eligible? Anyone who bought and held $ALVR stock through December 21, 2023. Do I need to sell to qualify? No — you're eligible if you bought during that period, even if you still hold the shares. How much is the payout? Estimated at $0.03 per share — but if only 25% of eligible investors file, it could go up to $0.12 per share. Can I still file? Yes — claims are currently being accepted. When do payouts happen? Usually 4–9 months after the court grants final approval. To file your claim: https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate May. 12 at 11:24 AM

$ALVR agreed to a $1M settlement with investors over claims it misled them about the effectiveness of its lead treatment, Posoleucel, during failed Phase 3 trials. Who’s eligible? Anyone who bought and held $ALVR stock between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you're eligible if you purchased during that period, regardless of whether you sold or still hold. How much is the payout? Estimated at $0.03 per share, depending on how many investors file. Can I still file? Yes — late claims are currently being accepted, subject to court approval. When do payouts happen? Usually 8–12 months after final approval. To file your claim: https://11th.com/cases/allovir-investor-settlement

0 · Reply

youspeaktome May. 8 at 7:09 PM

$ALVR $KLRS Doing some work here and this should be valued at 30% of cash. Their drug is still in Phase 1 very early trials

0 · Reply

youspeaktome May. 8 at 6:38 PM

$ALVR $KLRS @gilheydari it's a joke. Samsara has a huge conflict. The market is now valuing their pile of trash at less than 0

0 · Reply

gilheydari May. 7 at 4:45 PM

$ALVR Such merger and the only winner was this one Samsara BioCapital, L.P., valued their portfolio company with 5 people and no product at $400M

0 · Reply

11thestate May. 5 at 10:24 AM

$ALVR agreed to a $1M settlement with investors over claims it hid key trial failures for its lead drug, Posoleucel. Who’s eligible? Anyone who bought AlloVir stock between January 10, 2023 and December 22, 2023. Do I need to sell my shares to qualify? No — you're eligible if you bought during that period, even if you no longer hold the shares. How much is the payout? Estimated at $0.03 per share, but if only 25% of investors file, payouts could reach up to $0.12 per share. Can I still file? Yes — the court has already approved the settlement, and late claims are being considered, subject to approval. When do payouts happen? Typically 8–12 months after court approval. Since approval was granted in April 2025, payouts may occur in early 2026. To file your claim: https://11th.com/cases/allovir-investor-settlement

0 · Reply

JoshThe3rd May. 4 at 12:25 AM

$ALVR lets see if this bottoms below CV at 5.00. Been trying to figure out if Samsara is using the merger for an exit or they want to lock the float and pump it.

0 · Reply

Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Stockholders to Inquire about Securities Investigation

Jun 12, 2025, 10:00 AM EDT - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Investors to Learn More About the Investigation

Jun 10, 2025, 10:00 AM EDT - 6 days ago

AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jun 8, 2025, 10:00 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against AlloVir Inc. (ALVR) And Encourages Stockholders to Reach Out

Jun 5, 2025, 10:00 AM EDT - 11 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating AlloVir Inc. (ALVR) And Encourages Stockholders to Connect

Jun 3, 2025, 10:00 AM EDT - 13 days ago

AlloVir Inc. (ALVR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against AlloVir Inc. (ALVR) and Encourages Stockholders to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages AlloVir Inc. (ALVR) Investors to Inquire about Securities Investigation

Mar 18, 2025, 4:21 PM EDT - 3 months ago

Kalaris Announces Closing of Merger with AlloVir

KLRS

Mar 12, 2025, 4:01 PM EDT - 3 months ago

Kalaris and AlloVir Announce Stockholder Approval of Merger

Feb 10, 2025, 12:20 PM EST - 4 months ago

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

Nov 9, 2024, 10:26 AM EST - 7 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

EMKR

Nov 8, 2024, 6:00 AM EST - 7 months ago

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

Sep 16, 2024, 11:16 AM EDT - 9 months ago

Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm

Mar 19, 2024, 7:00 AM EDT - 1 year ago

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 17, 2024, 11:00 PM EDT - 1 year ago

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 11, 2024, 7:00 AM EDT - 1 year ago

MARCH 19 FINAL DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 9, 2024, 8:00 AM EST - 1 year ago

INVESTOR DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 8, 2024, 3:30 AM EST - 1 year ago

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 7, 2024, 5:45 AM EST - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

Mar 7, 2024, 3:30 AM EST - 1 year ago

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 6, 2024, 1:00 PM EST - 1 year ago

MARCH 19 DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 5, 2024, 2:15 PM EST - 1 year ago

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Mar 4, 2024, 3:00 PM EST - 1 year ago

IMPORTANT MARCH DEADLINE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses to Contact the Firm

Feb 9, 2024, 10:45 AM EST - 1 year ago

ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options

Feb 6, 2024, 8:00 AM EST - 1 year ago

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Jan 26, 2024, 8:00 AM EST - 1 year ago

IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

Jan 16, 2024, 6:50 AM EST - 1 year ago

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

GRI IBIO VYNE

11thestate Jun. 12 at 10:36 PM

Don’t forget that if you held $ALVR, there’s a significant settlement you can also claim. Consider it the dividend #AlloVir never paid. https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate Jun. 4 at 12:04 PM

Don’t forget that if you held $ALVR, there’s a significant settlement you can also claim. Consider it the dividend #AlloVir never paid. https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate May. 27 at 10:35 AM

$ALVR investors, if you follow us, you already knew about it. This is the good news you needed about $ALVR today. Go check it out. #AlloVir #ALVR https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate May. 20 at 4:29 PM

0 · Reply

11thestate May. 12 at 11:24 AM

0 · Reply

youspeaktome May. 8 at 7:09 PM

$ALVR $KLRS Doing some work here and this should be valued at 30% of cash. Their drug is still in Phase 1 very early trials

0 · Reply

youspeaktome May. 8 at 6:38 PM

$ALVR $KLRS @gilheydari it's a joke. Samsara has a huge conflict. The market is now valuing their pile of trash at less than 0

0 · Reply

gilheydari May. 7 at 4:45 PM

$ALVR Such merger and the only winner was this one Samsara BioCapital, L.P., valued their portfolio company with 5 people and no product at $400M

0 · Reply

11thestate May. 5 at 10:24 AM

0 · Reply

JoshThe3rd May. 4 at 12:25 AM

$ALVR lets see if this bottoms below CV at 5.00. Been trying to figure out if Samsara is using the merger for an exit or they want to lock the float and pump it.

0 · Reply

11thestate Apr. 28 at 11:16 AM

$ALVR agreed to a $1M settlement with investors over claims it misled about the effectiveness of its lead product, Posoleucel. Who’s eligible? Anyone who purchased or otherwise acquired AlloVir ($ALVR) common stock between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you're eligible even if you still hold the shares, as long as you bought during the class period. How much is the payout? Estimated at $0.03 per share, depending on the number of valid claims submitted. Can I still file? Yes — late claims are being accepted, subject to court approval. When will payments go out? Payouts usually happen 8–12 months after the final approval hearing. To file your claim: https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate Apr. 21 at 11:58 AM

$ALVR agreed to a $1M settlement with investors over claims it misled them about the effectiveness of its lead product, Posoleucel. Who’s eligible? Anyone who bought and held $ALVR stock between January 11, 2023 and December 21, 2023. Do I need to sell my shares to qualify? No — you're eligible if you purchased during that period, regardless of whether you sold or still hold. How much is the payout? Estimated at $0.03 per share, depending on how many investors file. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Usually 8–12 months after the court grants final approval. To file your claim: https://11th.com/cases/allovir-investor-settlement

0 · Reply

gilheydari Apr. 14 at 7:08 PM

$ALVR looks like we are there! .25-.35

0 · Reply

11thestate Apr. 14 at 11:46 AM

$ALVR agreed to a settlement with investors to end claims that it misled them about the effectiveness of its lead product, Posoleucel. If you bought $ALVR between January 11, 2023, and December 21, 2023, you can file for payment here: https://11th.com/cases/allovir-investor-settlement

0 · Reply

11thestate Apr. 7 at 10:21 AM

$ALVR has reached a settlement with investors over claims that it misled them about the effectiveness of its lead product, Posoleucel. If you bought $ALVR between January 11, 2023, and December 21, 2023, you can file for payment here: https://11th.com/cases/allovir-investor-settlement

0 · Reply

NVDAMillionaire Mar. 26 at 11:16 AM

$ALVR Merger with Kalaris looks like a lifeline for ALVR. Posoleucel trials were brutal, but TH103 could be game-changing. Watching closely for next moves. Might be a speculative play for risk-tolerant investors. Hoping leadership can execute and turn this ship around. good article: https://beyondspx.com/article/allovir-nasdaq-alvr-navigating-challenges-and-charting-a-new-path-forward

0 · Reply

TwoToesTrading Mar. 19 at 1:03 PM

$ALVR $KLRS Ticker change

0 · Reply

tradingcalendar Mar. 19 at 1:00 PM

AlloVir, Inc $ALVR business combination with Kalaris Therapeutics, effective today - Reverse merger, symbol change to $KLRS, name change to Kalaris Therapeutics - Prior ALVR shareholders will retain roughly 25% equity ownership in the combined entity

0 · Reply

11thestate Mar. 7 at 12:52 PM

0 · Reply

ajmrtxl Feb. 28 at 12:48 PM

$ALVR's latest data on SqueezeFinder

0 · Reply

StockAutoPro Feb. 19 at 11:03 PM

$ALVR: Priced at $10.41 climbing. Buy near $10.00 target $12.00 with viral disease solutions.

0 · Reply

Spizzle Jan. 18 at 7:35 PM

$ALVR is this the old purple bio?

1 · Reply

Market Cap	49.48M
Revenue (ttm)	0.00
Net Income (ttm)	-58.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	9,400
Avg Vol	23,718
Day's Range	N/A - N/A
Shares Out	5.04M
Stochastic %K	61%
Beta	0.63
Analysts	Strong Buy
Price Target	$34.48